New Enterprise Associates

News, insights, analysis and data

← Back to New Enterprise Associates profile

New Enterprise Associates related stories

All articles and analysis

  • Fund performance: San Francisco LP sees impressive start to recent venture funds
    Mark Boslet- 2 November 2013

    Funds from Polaris, Trinity and NEA are quick out of the blocks

  • Kumu Networks raises $15 mln in Series B funding
    Chris Witkowsky- 1 November 2013

    Kumu Networks, which developed technology with the potential to double the capacity of wireless networks, has received $15 million in Series B funding led by Third Point Ventures, and joined by existing investors NEA and Khosla Ventures. Kumu raises $10 million in Series A funding from NEA and Khosla Ventures in December 2012, bringing total investment to $25 million.

  • VC-backed cloud network services provider Virtela sells for $525 mln
    Alastair Goldfisher- 29 October 2013

    Venture-backed Virtela Technology Services Inc. announced it has been acquired by NTT Communications Corp. for $525 million in cash. Virtela, which provides cloud network services, had previously raised $65 million in venture funding from Norwest Venture Partners, New Enterprise Associates, Newton Technology Partners and a number of other investors, according to data from Thomson Reuters (publisher of peHUB). Norwest led all the rounds in Virtela, which was founded in 2000 and incubated at Norwest's office in Palo Alto, Calif. Promod Haque, senior managing partner at Norwest, currently serves as chairman of Virtela, which is based in Greenwood Village, Colo.

  • GlycoMimetics sets terms for IPO - Fortune
    Iris Dorbian- 28 October 2013

    According to Fortune, GlycoMimetics has set its previously announced IPO to 4 million shares priced between $14 and $16 per share. The company plans to list the stock on the NASDAQ under the ticker symbol "GLYC." Jefferies and Barclays are the lead underwriters. Based in Gaithersburg, MD, GlycoMimetics is a biotech company focused on developing glycomimetic drugs. It is backed by New Enterprise Associates, Genzyme Ventures, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures.

  • Juniper Networks leads Series B round for Gainspeed
    Iris Dorbian- 23 October 2013

    Gainspeed has received an undisclosed amount of Series B funding in a round led by Juniper Networks. Based in Sunnyvale, Calif., Gainspeed is a provider of solutions for cable networks. In addition to Juniper Networks, Gainspeed is backed by NEA, Andreessen Horowitz and Shasta Ventures.

  • CIT GAP Funds invests in professional recruiting marketplace
    Chris Witkowsky- 23 October 2013

    The Center for Innovative Technology's CIT GAP Funds has closed an investment in SL8Z, a global marketplace for crowdsourced recruiting. SL8Z's marketplace connects employers who are recruiting professional and executive level positions to a handpicked community of experienced recruiting professionals. CIT GAP Funds is a family of seed- and early-stage investment funds focusing on near-equity and equity investments in Virginia-based high-growth technology, life sciences and clean tech companies.

  • Nginx raises $10m in Series B Round
    angela sormani- 16 October 2013

    Nginx has secured $10 million in a fully subscribed Series B round of funding. The round was led by venture capital firm New Enterprise Associates and included full participation of existing Series A investors e.ventures, Runa Capital, MSD Capital, as well as participation from Aaron Levie, CEO and founder of Box. With this funding, Nginx has raised $13 million to date.

  • Jim Bankoff's Vox Media nears $40 mln funding target
    Reuters News- 15 October 2013

    San Francisco, Oct 15 (Reuters) - Vox Media, the publisher of sports website SB Nation, has raised $34 million of a $40 million new funding round, according to a filing at the Securities and Exchange Commission, sister news service Reuters reported.

  • Jim Bankoff's Vox Media nears $40 mln funding target
    Reuters News- 15 October 2013

    VC firm’s latest funding round on track

  • VC-backed Trevena files for IPO: CORRECTED
    Iris Dorbian- 10 October 2013

    Trevana said Thursday that it has filed for an IPO. The number of shares and pricing terms have yet to be decided. Trevana plans on trading the stock on the NASDAQ under the ticker symbol "TRVN." Barclays Capital and Jefferies are serving as lead underwriters. Based in King of Prussia, Penn., Trevena is a clinical stage biopharmaceutical company that develops therapeutics that G protein coupled receptors. It is backed by Alta Partners, New Enterprise Associates, Polaris Partners, Forest Labs and HealthCare Ventures.